Ticagrelor
- Generic Name
- Ticagrelor
- Brand Names
- Brilinta, Brilique
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28F2N6O4S
- CAS Number
- 274693-27-5
- Unique Ingredient Identifier
- GLH0314RVC
- Background
Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.
Ticagrelor was granted EMA approval on 3 December 2010.
Ticagrelor was granted FDA approval on 20 July 2011.
- Indication
Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.
- Associated Conditions
- Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)
Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Kafrelsheikh University
- Target Recruit Count
- 580
- Registration Number
- NCT06120725
- Locations
- 🇪🇬
Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt
Ticagrelor Single Antiplatelet Therapy in Patients With High Risk of Bleeding After DCB for Coronary Small Vessel Disease
- Conditions
- Coronary Heart Disease
- Interventions
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Fu Wai Hospital, Beijing, China
- Target Recruit Count
- 292
- Registration Number
- NCT06088433
- Locations
- 🇨🇳
Fuwai Hospital, Beijing, Beijing, China
Stent-Assisted Coiling Followed by Ticagrelor Monotherapy Instead of Dual Antiplatelet Therapy in Unruptured Intracranial Aneurysm
- Conditions
- Stent ComplicationIntracranial Aneurysm
- Interventions
- Drug: Dual Antiplatelet Therapy
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2024-03-13
- Target Recruit Count
- 180
- Registration Number
- NCT06015477
- Locations
- 🇨🇳
Hua Lu, Nanjing, Jiangsu, China
One-Month DAPT in CABG Patients
- Conditions
- Chronic Coronary Disease
- Interventions
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 700
- Registration Number
- NCT05997693
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇦🇹Medical University Graz, Graz, Austria
🇦🇹Medical University Innsbruck, Innsbruck, Austria
Safety of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction and the Effect on Intramyocardial Haemorrhage
- Conditions
- ST Elevation Myocardial Infarction
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 200
- Registration Number
- NCT05986968
- Locations
- 🇳🇱
Noordwest Ziekenhuisgroep Alkmaar, Alkmaar, Netherlands
🇳🇱Amsterdam UMC, Amsterdam, Netherlands
🇳🇱Radboudumc, Nijmegen, Netherlands
Individualized and Combined Effects of Diabetes and Smoking on the Antiplatelet Activity of Ticagrelor in Acute Myocardial Infarction Patients Undergoing Primary PCI
- Conditions
- Individualized and Combined Effects of Smoking and Diabetes on the Antiplatelet Activity in Patients Undergoing Primary Percutaneous Coronary Intervention
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Mina Wageh Mohareb
- Target Recruit Count
- 60
- Registration Number
- NCT05911659
- Locations
- 🇪🇬
Faculty of medicine of girls, Cardiology department, Al-Azhar University in Cairo, Cairo, Egypt
Ticagrelor vs. Clopidogrel in Post PCI Patients
- Conditions
- Stable Chronic Angina
- Interventions
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Shiraz University of Medical Sciences
- Target Recruit Count
- 476
- Registration Number
- NCT05858918
- Locations
- 🇮🇷
Professor Kojuri Cardiology Clinic, Shiraz, Iran, Islamic Republic of
De-escalation of Ticagrelor in Post PPCI
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2023-04-26
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 400
- Registration Number
- NCT05831462
Effects of Ticagrelor Versus Prasugrel on Coronary Microcirculation in Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-3 Randomised Study
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- Germano Di Sciascio
- Target Recruit Count
- 50
- Registration Number
- NCT05643586
- Locations
- 🇧🇪
Aalst cardiovascular center, Aalst, Belgium
Multicentric Study on Clopidogrel Resistance in DAPT for CAS (MULTI-RESCLOSA)
- Conditions
- Clopidogrel, Poor Metabolism ofCarotid Stenosis
- Interventions
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- IRCCS Policlinico S. Donato
- Target Recruit Count
- 1140
- Registration Number
- NCT05566301
- Locations
- 🇮🇹
IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.